Observational studyCancer medicine2020
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Observational study in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.Targeted oncology · 2021Pooled it
- The interplay of the lncRNA AFAP1-AS1 and the soluble immune checkpoint proteins sPD-1/sPD-L1 in breast cancer: tumor-immune cross-talk.Bioscience reports · 2026Article
- The Prognostic Value of Serum Soluble Programmed Death 1 (sPD-1) and Programmed Death Ligand 1 (sPD-L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis About Cohort Studies.Health science reports · 2024Review
- JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases.International journal of molecular sciences · 2024Article
- The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?Cancers · 2023Article
- Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.Journal of translational medicine · 2023Article
- CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.Cell biology and toxicology · 2022Article
- Circulating proteins as predictive and prognostic biomarkers in breast cancer.Clinical proteomics · 2022Review
- Prognostic Impact of Pretreatment Serum CYFRA Status in 1047 Patients with Esophageal Squamous Cell Carcinoma Who Underwent Radical Resection: A Japan Esophageal Society Promotion Research.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2022Article
- Preoperative low serum creatine kinase is associated with poor overall survival in the male patients with esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer.Frontiers in oncology · 2022Article
- Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis.Journal of oncology · 2022Review
- Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.Molecular and clinical oncology · 2021Article
- c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.Clinical and translational medicine · 2021Article
- The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.Frontiers in oncology · 2021Article
- Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges.Annals of gastroenterological surgery · 2020Review
- Article
- High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.Cancer medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death ligand 1 (PD-L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD-L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal cancer patients is lacking. Therefore, we evaluated the clinicopathological and prognostic impact of serum PD-L1 levels in surgically treated esophageal cancer.
methodsA total of 150 patients who underwent radical resection for esophageal cancer were included in the study. Preoperative serum PD-L1 levels were analyzed using the enzyme-linked immunosorbent assay kit. A cutoff level of 65.6 pg/mL was used to divide the patients into two groups, and univariate and multivariate analyses were conducted to compare the clinicopathological characteristics and prognoses between these two groups.
resultsAlthough significant associations between serum PD-L1 levels and clinicopathological variables were observed, serum PD-L1 level was significantly associated with high neutrophil counts, high CRP levels, low albumin levels, and high squamous cell carcinoma antigen levels. Furthermore, serum PD-L1 level was associated with poor overall survival independent to TNM factors.
conclusionsHigh preoperative level of serum PD-L1 is a prognostic factor for poor overall survival in patients with surgically treated esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.